SIX Swiss Exchange · Healthcare
Invest in Santhera Pharmaceuticals stock from India
Indian and foreign residents can buy Santhera Pharmaceuticals (SANN) shares directly through Paasa.
By Paasa · Updated
Santhera Pharmaceuticals at a glance
- Price
- CHF 15.50+CHF 0.42 (2.79%)
- Market cap
- CHF 229.89M
- Day range
- CHF 14.68 – CHF 15.58
- P/E
- -4.06
- Dividend yield
- None
- Volume
- 165.56K
- 1 month
- +3.89%
- 6 months
- -0.39%
- YTD
- +23.02%
- 1 year
- +43.78%
- 5 years
- +2.79%
Santhera Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 77.2M | CHF 39.1M | CHF 103.4M | CHF 7.5M | −CHF 1.6M |
| Gross profit | CHF 14.5M | CHF 23.0M | CHF 100.2M | CHF 3.9M | −CHF 5.4M |
| Operating income | −CHF 37.8M | −CHF 33.4M | CHF 68.8M | −CHF 52.0M | −CHF 56.9M |
| Net income | −CHF 49.2M | −CHF 42.0M | CHF 54.8M | −CHF 71.1M | −CHF 55.5M |
| Earnings per share | −CHF 3.78 | −CHF 3.69 | CHF 5.18 | −CHF 11.67 | −CHF 16.25 |
| EBITDA | −CHF 32.1M | −CHF 15.9M | CHF 79.2M | −CHF 46.8M | −CHF 34.6M |
| Total assets | CHF 148.1M | CHF 152.5M | CHF 109.6M | CHF 63.7M | CHF 91.1M |
| Total debt | CHF 97.8M | CHF 41.2M | CHF 23.0M | CHF 44.4M | CHF 43.0M |
| Cash and short-term investments | CHF 22.4M | CHF 40.9M | CHF 30.4M | CHF 1.4M | CHF 21.2M |
| Shareholders' equity | −CHF 11.8M | CHF 27.7M | CHF 59.9M | −CHF 43.7M | CHF 1.3M |
| Operating cash flow | −CHF 34.8M | −CHF 35.5M | CHF 47.3M | −CHF 29.8M | −CHF 37.4M |
| Free cash flow | −CHF 34.8M | −CHF 35.7M | CHF 23.5M | −CHF 33.8M | −CHF 37.4M |
| Capital expenditure | −CHF 52.0K | −CHF 151.0K | −CHF 23.7M | −CHF 4.0M | −CHF 15.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| DocMorris | DOCM.SW | CHF 13.41 | CHF 655.60M |
| COLTENE | CLTN.SW | CHF 46.10 | CHF 275.47M |
| Ascom | ASCN.SW | CHF 5.91 | CHF 201.89M |
| Newron Pharmaceuticals | NWRN.SW | CHF 8.05 | CHF 167.49M |
| Molecular Partners | MOLN.SW | CHF 3.32 | CHF 124.54M |
| SHL Telemedicine | SHLTN.SW | CHF 1.05 | CHF 38.91M |
| Relief Therapeutics | RLF.SW | CHF 2.89 | CHF 36.28M |
| EvoNext | EVE.SW | CHF 2.08 | CHF 15.00M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Santhera Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search SANN and buy
Find Santhera Pharmaceuticals by name or by its ticker, SANN, and place your order.
Why invest in Santhera Pharmaceuticals from India
What Santhera Pharmaceuticals does
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Santhera Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy Santhera Pharmaceuticals (SANN) shares directly through Paasa. Santhera Pharmaceuticals is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Santhera Pharmaceuticals shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.